GlassScriptPhysician profile
Bernard Ronald Lopez
NPI 1568458891
$3,811.27
in general payments reported to CMS, 2019-2025
31 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $461 · 2021: $311 · 2022: $644 · 2023: $354 · 2024: $530 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.04 | 2021-2025 | |
| Allergan, INC. | $385.42 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $263.30 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $215.47 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.67 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $210.74 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $202.61 | 2021-2025 | Qelbree, Qelbree |
| Eisai INC. | $166.76 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $164.98 | 2019-2022 | |
| Corium, LLC | $164.26 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $159.55 | 2019 | |
| Alkermes, INC. | $153.47 | 2022-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $131.71 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $111.67 | 2019-2024 | |
| Tris Pharma INC | $100.31 | 2019-2025 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $81.42 | 2019 | |
| Lundbeck LLC | $78.31 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $74.36 | 2019-2022 | |
| Almatica Pharma LLC | $72.11 | 2023-2024 | Loreev Xr, Gralise |
| E.R. Squibb & Sons, L.L.C. | $51.85 | 2025 | Cobenfy |
| Orexo US, INC. | $40.63 | 2019 | |
| Alfasigma USA, INC. | $31.83 | 2020 | |
| Axsome Therapeutics, INC. | $28.87 | 2023-2025 | Auvelity, Sunosi |
| Indivior INC. | $22.76 | 2019 | |
| Shire North American Group INC | $19.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.77 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.80 | 2019 | |
| Neuronetics, INC. | $13.42 | 2019 | |
| Bausch Health US, LLC | $12.51 | 2019 | |
| Adlon Therapeutics L.P. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.